发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:The limited brain delivery of carbamezapine (CBZ) presents a major hurdle in the successful epilepsy treatment. The potential of carbamezapine-loaded nanostructured lipid carriers (CBZ-NLCs) for improved brain delivery is investigated in the current study. CBZ-NLCs were prepared by using binary mixture of trilaurin and oleic acid as a lipid core stabilized with Poloxamer 188, Tween 80 and Span 80. CBZ-NLCs were evaluated for physicochemical properties, in vitro release, in vivo brain kinetics, anticonvulsant and anxiolytic activities. The optimized CBZ-NLCs demonstrated nanometric particle size (97.7 nm), surface charge of -22 mV and high drug incorporation (85%). CBZ-NLCs displayed biphasic release pattern with initial fast followed by sustained drug release. CBZ-NLCs significantly enhanced the AUC of CBZ (520.4 µg·h/mL) in brain compared with CBZ dispersion (244.9 µg·h/mL). In vivo anticonvulsant activity of CBZ-NLCs in PTZ-induced seizure model showed a significant increase in the onset time (143.0 sec) and reduction in duration (17.2 sec) of tonic-clonic seizures compared with CBZ dispersion (75.4 and 37.2 sec). The anxiolytic activity in light-dark box and elevated-plus maze models also demonstrated superiority of CBZ-NLCs to CBZ dispersion. From the results, CBZ-NLCs presents a promising strategy to improve brain delivery and therapeutic outcomes of CBZ in epilepsy.
展开更多
最新影响因子:6.51 | 期刊ISSN:0378-5173 | CiteScore:4.06 |
出版周期:Biweekly | 是否OA:YES | 出版年份:1978 |
期刊官方网址:http://www.elsevier.com/wps/find/journaldescription.cws_home/505513/description
期刊投稿地址:http://ees.elsevier.com/ijp/
自引率:11.50% | 研究方向:医学-药学 |
出版地区:NETHERLANDS |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The International Journal of Pharmaceutics provides a medium for the publication of innovative papers, reviews, mini-reviews, short communications and notes dealing with physical, chemical, biological, microbiological and engineering studies related to the conception, design, production, characterisation and evaluation of drug delivery systems in vitro and in vivo. "Drug" is defined as any therapeutic or diagnostic entity, including oligonucleotides, gene constructs and radiopharmaceuticals. Areas of particular interest include: physical pharmacy; polymer chemistry and physical chemistry as applied to pharmaceutics; excipient function and characterisation; biopharmaceutics; absorption mechanisms; membrane function and transport; novel routes and modes of delivery; responsive delivery systems, feedback and control mechanisms including biosensors; applications of cell and molecular biology to drug delivery; prodrug design; bioadhesion (carrier-ligand interactions); and biotechnology (protein and peptide delivery). Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher. Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.
《国际药学杂志》提供了一种出版创新论文、评论、小型评论、简短交流和笔记的媒介,涉及物理、化学、生物、微生物和工程研究,涉及药物在体内和体外传递系统的概念、设计、生产、特性和评价。“药物”定义为任何治疗或诊断实体,包括寡核苷酸、基因构建物和放射性药物。特别感兴趣的领域包括:物理药学;高分子化学和物理化学在制药中的应用赋形剂的功能和特性;生物药剂学;吸收机制;膜的功能和运输;新颖的送货路线和方式;反应性传递系统、反馈和控制机制,包括生物传感器;细胞和分子生物学在药物传递中的应用前药设计;辅料(carrier-ligand互动);生物技术(蛋白质和肽传递)。编辑政策出版的首要标准是原创性、高科学质量和对多学科读者的兴趣。未经实验细节充分证实的论文将不予发表。任何技术问题都将提交给作者,尽管编辑保留在不改变技术内容的情况下修改文本的权利。以多重作者身份提交的稿件将在假定所有列出的作者都同意提交的情况下进行审查,并且最终稿件的副本已得到所有作者的批准,并已由进行工作的实验室的主管当局默认或明确地批准。未经编辑出版者同意,稿件不得在其他地方以相同的形式、相同的文字或者其他文字发表。在提交论文发表时,作者必须在附信中说明他们的工作或研究方法所体现的新颖性。常规的生物等效性研究不太可能受到青睐。本署将不会发表任何论文,不完全披露所使用的配方的性质或对产品、药物或辅料的性能至关重要的材料的详情。结果可预测的工作,例如在环糊精中加入另一种药物以产生更强的溶解性,将不会发表,除非它对基本原理提供了新的见解。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
PHARMACOLOGY & PHARMACY (药学) 2区 |
46/261 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
865 | 808 | 57 |
引文计数(2018)
文献(2015-2017)
10228次引用
2518篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Pharmacology, Toxicology and Pharmaceutics
小类(学科):Pharmaceutical Science
|
#16/174
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:数理科学 力学 流体力学
审稿时间: 1个月内
liting7111
研究方向:工程技术 材料科学:生物材料
审稿时间: 3个月内
影响因子:13.029
ISSN:1522-8517
研究方向:医学-临床神经学
影响因子:4.506
ISSN:0167-594X
研究方向:医学-临床神经学
影响因子:7.723
ISSN:2162-402X
研究方向:ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
影响因子:4.912
ISSN:1524-9557
研究方向:医学-免疫学
影响因子:12.02
ISSN:2326-6066
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:3.698
ISSN:1750-9378
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:6.63
ISSN:0340-7004
研究方向:医学-免疫学
影响因子:3.077
ISSN:1534-7354
研究方向:医学-全科医学与补充医学
影响因子:0
ISSN:1868-8497
研究方向:ONCOLOGY-ENDOCRINOLOGY & METABOLISM
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
INTERNATIONAL JOURNAL OF PHARMACEUTICS 投稿经验
(由下方点评分析获得,3人参与,43487人阅读)